Seneste opdatering :
19/11/2024
anticancer medicin   Irinotecan  
Injektion
Stabilitet i (vandige) opløsninger Stabilitet i blandinger Faktorer der påvirker stabiliteten Kompatibilitet Administrationsvej Bibliografi pdf
   Kemisk struktur  

Handelsnavn   Handelsnavn     

Handel navne er vejledende og hjælpestoffer sammensætning kan være forskellig afhængigt af landet og laboratorier

Asinib Mexico
Axinotecan Tyskland
Campto Belgien, Danmark, Finland, Forenede Arabiske Emirater, Frankrig, Grækenland, Holland, Indien, Iran, Irland, Italien, Japan, Kroatien, Luxemborg, Malaysia, Marokko, Norge, Polen, Portugal, Schweiz, Spanien, Storbritanien, Sverige, Sydafrika, Thailand, Tunesien, Tyrkiet, Ungarn, Østrig
Camptosar Brasilien, Canada, USA
Irinoliquid Østrig
Irnocam Brasilien
Bibliografi   Injektion   Bibliografi : Irinotecan  
Type offentliggørelse
1423 Journal Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1617 Journal Li WY, Koda RT.
Stability of irinotecan hydrochloride in aqueous solutions.
Am J Health-Syst Pharm 2002 ; 59: 539-544.
1662 Journal Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1918 Journal Dodds HM, Craik DJ, Rivory LP.
Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition.
J Pharm Sci 1997 ; 86, 12: 1410-1416.
1920 Journal Akimoto K, Kaway A, Ohya K et al.
Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution.
Drug Stability 1996 ; 1: 118-122.
1921 Journal Akimoto K, Kawai A, Ohya K.
Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution.
Drug Stability 1996 ; 1; 141-146.
1953 Journal Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976 Journal Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241.
2027 Journal Walker SE, Shirley L, Puodziunas A.
Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers.
Can J Hosp Pharm 2005 ; 58: 212-222.
2143 Journal Dodds HM, Robert J, Rivory LP.
The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry.
J Pharm Biomed Anal 1998 ; 17: 785-792.
2168 Journal Ozdemir FA, Anilanmert B, Pekin M.
Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution.
Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2241 Journal Thiesen J, Krämer I.
Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags.
J Oncol Pharm Practice 2000 ; 6, 3: 115-121.
2340 Journal Walker S.E, Law S, Puodziunas A.
Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers
Can J Hosp Pharm 2005 ; 58, 4: 212-222.
2671 Journal Kaiser J, Thiesen J, Krämer I.
Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization.
J Oncol Pharm Practice 2010 ; 16: 53-61.
3129 Laboratorium Irinotécan (Campto®) – Résumé des caractéristiques du produits
Pfizer 2008
3369 Laboratorium Levofolinate de sodium Medac - Résumé des caractéristiques du produits
MEDAC France 2011
3670 Journal Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3873 Journal Tan X, Hu J.
Incompatibility between irinotecan and fluorouracil injections
Am J Health-Syst Pharm 2016 ; 73:755.

  Mentions Légales